DIRS.INFO The most relevant business & tech news

☆ AI, wearables and more — these markets are booming as the world ages. The pros share 4 stock picks
▼ + stars: | 2023-12-27 | by ( Weizhen Tan | ) www.cnbc.com time to read: +6 min

"The aging population discussion in recent years has mostly revolved around future challenges to labor productivity and its economic growth implications," he said. AI, robotics and wearables The aging population stands to gain significantly from breakthroughs in robotics powered by artificial intelligence, according to Afzal. Arelis Agosto, research analyst at Global X ETFs, said wearables technology is one interesting area to invest in for the aging theme. "We view self-sustaining monitoring and therapeutic systems as the future of patient care, though it is particularly beneficial for elderly patients," Agosto said. Global X ETFs, a fund management company, offers a way to tap the aging theme through its Aging Population ETF.

Persons: Shams Afzal, There's, Afzal, Stryker, Dani Saurymper, Saurymper, Arelis Agosto, Agosto Organizations: Carnegie Investment, CNBC Pro, Stryker, EU, Longevity, Global, Carnegie, Abbott Laboratories, Agosto Locations: U.S, GLP, Agosto

☆ GSK lifts annual forecasts on strong launch of RSV vaccine
▼ + stars: | 2023-11-01 | by ( Eva Mathews | ) www.reuters.com time to read: +3 min

Arexvy, launched in the United States recently, recorded third quarter sales of 709 million pounds ($862 million), trouncing analysts' expectations of 358 million pounds, according to a company-compiled consensus. GSK accounts for close to two-thirds of RSV shots given in the United States since early September, according to IQVIA data. Full-year sales are seen between 900 million pounds and 1 billion pounds for the shot, GSK said. The company faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware and scheduled for trial starting January 2024. For the third quarter, Shingrix, the company's top-selling drug for shingles, generated 825 million pounds in sales.

Persons: Dado Ruvic, Abrysvo, Dani Saurymper, Emma Walmsley, Eva Mathews, Maggie Fick, Tomasz Janowski, Mark Potter Organizations: GSK, GlaxoSmithKline, REUTERS, stg, CVS, Pfizer, Pacific Asset Management, GSK's, Thomson Locations: London, United States, U.S, Europe, Japan, Delaware, Bengaluru

GSK reckons the spin-off has allowed the company to sharpen its focus on vaccines and infectious diseases and with $7 billion generated by the Haleon spin-off, it can fund deals to bolster a lacklustre drug pipeline. The company also reported an adjusted profit of 38.8 pence per share for the quarter, on sales of about 7.18 billion pounds ($9.26 billion). Analysts were expecting a profit of 34.7 pence per share on sales of about 6.77 billion pounds, according to company-compiled consensus estimates. Sales of Shingrix, the company's top-selling drug, generated 880 million pounds, beating analyst estimates of 872 million pounds. Sales of HIV treatments generated 1.58 billion in the quarter, ahead of the company-compiled consensus of about 1.5 billion pounds in the quarter.

Persons: Zantac, Emma Walmsley, Walmsley, Markus Manns, Dani Saurymper, Maggie Fick, Radhika Anilkumar, Janane Venkatraman, Savio D'Souza, Josephine Mason Organizations: GSK, British, Analysts, U.S, Union Investment, Pacific Asset Management, Thomson Locations: London, Bengaluru

☆ Aging populations are creating major opportunities, fund manager says. Here's where he's investing
▼ + stars: | 2023-06-30 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

Health care is just one area to consider, according to Saurymper, who manages Pacific Asset Management's Longevity & Social Change Fund. As well as health care and pharmaceutical stocks, its holdings span fitness and nutrition, personal care, aesthetics and financials. "Now I think about health care along the lines of units of health care, rather than a drug. Investing in companies that leverage technology to deliver efficient health care is also crucial in cutting costs, he added. Education Looking beyond more obvious aging themes, the fund manager said education and well-being also offer investors a major opportunity.

Persons: Dani Saurymper, Saurymper, Eli Lilly, They're, it's, There's, CNBC's Ganesh Rao Organizations: CNBC, Alzheimer's, Tech, Apple, Apple Watch, CVS Locations: U.S

☆ Buy this stock set to plug a 'massive skills gap' in aging America, fund manager says
▼ + stars: | 2023-06-27 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

There's one stock that resonates the most for fund manager Dani Saurymper as social trends shift amid an aging population. As such, it's well placed to plug the "massive skills gap" in the health care industry, according to Saurymper. As well as health care and pharmaceutical stocks, its holdings span fitness and nutrition, personal care, aesthetics and financials. "Now I think about health care along the lines of units of health care, rather than a drug. However, key industries exposed to the aging population go beyond the challenges of aging, he added.

Persons: Dani Saurymper, Adtalem, Saurymper, There's Organizations: CNBC Locations: It's, U.S

☆ This U.S. biotech stock is up 90% this year and will continue to soar, fund manager says
▼ + stars: | 2023-06-23 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Shares of U.S. biotech firm Exact Sciences have surged by almost 90% this year. But the run may not be over just yet, according to fund manager Dani Saurymper. Earlier this week it said its next-generation screening test, Cologuard 2.0, showed a 30% lower false positive rate for detecting the disease in a study compared to its already approved test. This is where Exact Sciences fits in. Saurymper believes that the stock has corrected and has a significant runway ahead.

Persons: Dani Saurymper, Saurymper, CNBC's, EXAS, Kyle Mikson, Canaccord Genuity, CNBC's Arabile, it's Organizations: Sciences, Nasdaq, Companies, FDA

☆ CNBC Pro Talks: This fund manager is betting big on the aging theme
▼ + stars: | 2023-06-21 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCNBC Pro Talks: This fund manager is betting on the aging theme, including one ‘huge’ opportunityCNBC’s Arabile Gumede spoke to Pacific Asset Management’s Dani Saurymper on how to invest in the world’s aging population. From AstraZeneca and Lululemon to Pets at Home, Saurymper’s fund looks to tap themes that have “proven commercial viability.”

Persons: Arabile Gumede, Dani Saurymper Organizations: AstraZeneca, Lululemon

☆ Pro Talks: This fund manager is betting big on the aging theme, including one 'huge' opportunity
▼ + stars: | 2023-06-20 | by ( Cnbc.Com Staff | ) www.cnbc.com time to read: +1 min

The world's population is getting older — and it's creating significant investment opportunities, according to Pacific Asset Management's Dani Saurymper. Join CNBC's Arabile Gumede as he discusses with Saurymper how to play the long-term aging theme on Pro Talks . Join CNBC Pro Talks on Wednesday, June 21, at 12 p.m. BST / 7 p.m. SGT / 7 a.m. Learn more from our previous Pro Talks: Tesla vs. BYD: Here's why one fund manager prefers the Buffett-backed automaker Nvidia's stock could rise fivefold in 10 years on A.I. trend, says fund manager Thinking of buying tech stocks?

Persons: Dani Saurymper, Saurymper, Goldman Sachs Organizations: Longevity, AstraZeneca, Pets, Pacific Asset Management, AXA Investment Managers, Barclays Investment Bank, Bank of America Locations: U.S, A.I

Search resuls for: "Dani Saurymper"

8 mentions found